Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Gilead Sciences has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive human rights ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...